Jiangsu Atom Bioscience & Pharmaceutical Co. Ltd (Atom Bioscience) has raised 150 million yuan ($22 million) in a Series B round led by Livzon Pharmaceutical, a wholly-owned investment platform Zhuhai Lizhu Pharmaceutical Equity Investment Management Co., Ltd. In a separate development, China’s premium big data solution company Chengdu Shuzhilian Technology Company has also secured a similar amount from GF Venture Capital and existing investor Yinxinggu Capital.
End the Year with a Deal You Can’t Miss!
Subscribe now and save 40% on our premium subscription.
Enjoy unlimited access for a full year at just $199 (usual price $339).
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Offer valid for a limited time – don’t wait to unlock the insights that drive deal-making in Asia!
Subscribe nowAlready a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
